Sinotau Pharmaceutical Group
Sinotau Pharmaceutical Group
Explore linked clinical trials.12 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms | Advanced Neuroendocrine Neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-07-17 | NCT06398444 | |
| Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 3 | 2026-03-03 | NCT07439133 | |
| PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 2 | 2026-03-02 | NCT07443696 | |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2025-09-05 | NCT05459844 | |
| A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2025-09-02 | NCT07149831 | |
| Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not applicable | 2025-08-11 | NCT07115277 | |
| Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2025-08-11 | NCT07115238 | |
| A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer | mCRPC | Recruiting | Phase 1 | 2025-07-31 | NCT07096128 | |
| Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, astrocytoma (excluding glioblastoma), benign urinary system neoplasm, carcinoma, epithelial neoplasm, glioblastoma, glioma, kidney cancer, kidney disorder, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, renal cell carcinoma, urinary system disorder | Recruiting | Early phase 1 | 2025-07-16 | NCT07067905 | |
| A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2025-06-26 | NCT06732505 | |
| A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2024-01-18 | NCT06211647 | |
| A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2024-01-09 | NCT06197139 |